NSAIDs in Heart Failure: Recommendations and Precautions

Risks of NSAIDs in Heart Failure

• The European Society of Cardiology recommends that NSAIDs should be avoided in patients with heart failure unless absolutely essential, as they increase the risk of heart failure exacerbation, hospitalization, and mortality 1, 2, 3
• NSAIDs may attenuate the effect of diuretics, leading to fluid retention and edema, according to the European Journal of Heart Failure 1, 4

Alternative Pain Management Approaches

• The European Journal of Heart Failure suggests that for chronic non-cancer pain in heart failure patients, non-pharmacologic and non-opioid pharmacologic therapy are preferred 3
• Paracetamol (acetaminophen) appears to be safe in heart failure patients, as stated by the Cardiovascular Research journal 3
• For gout pain in heart failure patients, colchicine is recommended instead of NSAIDs, according to the European Journal of Heart Failure 5, 6
• If pain persists despite non-pharmacological and non-opioid pharmacologic therapy, opioids may be considered at the lowest effective dose for the shortest duration, as recommended by the Cardiovascular Research journal 3
• In patients with severely impaired renal function, opioids with a safer metabolic profile (methadone, buprenorphine, or fentanyl) are preferred, according to the Cardiovascular Research journal 3

Monitoring and Management if NSAIDs Must Be Used

• Watch for signs of worsening heart failure, including increased dyspnea, edema, and weight gain, as advised by the European Journal of Heart Failure 1, 4

Patient Education

• The European Journal of Heart Failure advises patients with heart failure to avoid over-the-counter NSAIDs not prescribed by a physician 1, 7
• Educate patients about the potential risks of NSAIDs and the importance of reporting any worsening of heart failure symptoms, as recommended by the European Journal of Heart Failure 1, 4
• Inform patients about alternative pain management strategies that are safer in the context of heart failure, according to the Cardiovascular Research journal 3

Diclofenac Use in Patients with Heart Failure – Evidence‑Based Risks and Recommendations

Risks of Diclofenac in Heart Failure

• Contraindication due to increased morbidity and mortality – Diclofenac is contraindicated in patients with heart failure because it markedly raises the risk of clinical worsening, hospital admission, and death compared with placebo. (European Heart Journal, 2016) 8
• Sodium‑water retention – By inhibiting renal prostaglandin synthesis, diclofenac promotes sodium and fluid retention, aggravating congestion in heart‑failure patients. (Circulation, 2013) 9
• Attenuation of diuretic efficacy – Non‑steroidal anti‑inflammatory drugs, including diclofenac, diminish the therapeutic effect of loop diuretics, which are cornerstone drugs in heart‑failure treatment. (European Journal of Heart Failure, 2012) 10

Pharmacologic Interactions

• Adverse interactions with guideline‑directed heart‑failure therapies – Diclofenac interferes with ACE inhibitors, ARBs, diuretics, and mineralocorticoid‑receptor antagonists, reducing their effectiveness and potentially worsening heart failure. (Circulation, 2013; European Journal of Heart Failure, 2012) 9, 10, 11
• Risk from over‑the‑counter NSAIDs – Even low‑dose, non‑prescription NSAIDs pose a significant hazard for heart‑failure patients and should be avoided. (European Journal of Heart Failure, 2012) 10, 11

Patient Education and Safety Measures

• Education on NSAID avoidance – Patients should be instructed to refrain from using any NSAIDs, including diclofenac, and to promptly report any increase in dyspnea, edema, or weight gain that could signal heart‑failure decompensation. (European Journal of Heart Failure, 2012) 10, 11

All statements are derived from peer‑reviewed sources and reflect the current evidence base; no specific strength of recommendation was provided in the cited literature.